AngioDynamics beats estimates on Med Tech strength, stock up nearly 3%

AngioDynamics reported Q3 fiscal 2026 revenue of $78.4M (+8.9% YoY) beating the $76.7M consensus and an adjusted loss per share of -$0.07 vs. -$0.09 expected; shares rose ~2.85% pre-market. Management raised FY26 revenue guidance to $313.5–$315.5M (midpoint $314.5M) and tightened adjusted EPS guidance to -$0.30 to -$0.23 (midpoint -$0.265), while adjusted EBITDA improved to $1.8M and cash totaled $37.8M with no debt. Gross margin compressed 110 bps to 52.9% due to tariffs, inflation and manufacturing transition costs, but continued product-level strength (Med Tech +19% YoY; NanoKnife +21%) supports the constructive outlook.

Analysis

AngioDynamics sits at an inflection where durable commercial adoption of mechanical thrombectomy products can generate nonlinear margin and free-cash-flow leverage once fixed manufacturing transition costs are absorbed. Because these devices increase per-procedure spend but shorten downstream resource use, hospitals adopting AlphaVac/AngioVac at scale create recurring consumable demand and higher attach rates for imaging/ancillary disposables — a multi-quarter revenue cadence that can surprise to the upside if penetration follows a logistic curve rather than linear growth.

The immediate margin headwind from tariffs and re-shoring costs is a tactical, not structural, risk: with a debt-free balance sheet the company can fund capacity reconfiguration or secure long-term supplier contracts to reclaim 150–300 bps of gross margin within 6–12 months after stabilization. Key macro and policy catalysts (tariff relief, device reimbursement adjustments, or large IDN conversion wins) will amplify upside, while downside is concentrated in reimbursement cuts, competitor-funded grants/price promotions (Penumbra, large OEMs), or an unexpected catheter-safety scare that compresses adoption — each capable of eroding volumes within a quarter or two.

Consensus is mildly positive but underweights operational optionality (M&A or commercial partnerships) made possible by a clean balance sheet and consistent double-digit segment growth; conversely, the market may be over-assigning permanency to current tariff-driven margin pressure. Monitor quarterly procedural metrics, distributor inventory turns, and any public tender wins as high-signal, short-horizon catalysts for re-rating.

Key Decisions for Investors

• Core long ANGO (equity) — 9–18 month horizon. Size: 2–4% of portfolio. Risk control: set a hard stop at -25% from entry. Rationale: capture margin recovery and continued procedure adoption; target upside 40–60% if adoption and tariff relief materialize.
• Long-dated call spread (ANGO, 12–18 month) — buy a moderately OTM call (≈25% OTM) and sell a further OTM call (≈60–80% OTM) to finance position. Reward: asymmetric 3x+ upside vs defined cost; thesis levered to commercial acceleration and margin normalization while limiting premium decay risk.
• Pair trade for neutral market exposure — Long ANGO / Short PEN (1:1) for 6–12 months. Mechanism: isolate product-level adoption and margin mix vs competitor. Exit triggers: divergence in reported procedure volumes or a material pricing promotion by PEN.
• Event hedge: buy 3–6 month puts on ANGO equal to 10–15% notional as insurance ahead of next quarterly print or a major tariff/reimbursement decision. Cost justified by concentrated single-product risk that can gap on news.